Thyroid Eye Disease
Thyroid eye disease (TED), also known as Graves ophthalmopathy, represents an autoimmune inflammatory disorder with characteristic clinical signs.
Although TED most often occurs in individuals with Graves hyperthyroidism it can also occur in patients with hypothyroidism or in the absence of thyroid dysfunction. The course of the disease does not necessarily parallel the activity of the thyroid gland or treatment of the thyroid abnormalities.
Typical ocular signs:
- Swelling (chemosis)of the eye
- Restrictive movement (strabismus)secondary to asymmetric swelling the extra-Ocular muscles
- Eyelid retraction-“thyroid stare”
- The prominence of one or both eye (proptosis)
- Visual field loss-compressive optic neuropathy
- The fluctuation of all the above
Treatment
Treatment ranges from watchful observation to drug therapies all the way to surgical intervention
Dr. Perman will discuss your options and customize a treatment plan for your specific needs.
An exciting new development is the December 2019 unanimous approval of the drug Teprotumumab (Horizon Biologics), a fully human monoclonal antibody for the treatment of Thyroid Eye Disease (TED).
Dr. Perman will discuss whether this new treatment modality is appropriate for your condition, and will facilitate your treatment protocol.
An exciting new development is the December, 2019 unanimous approval of the drug TEPEZZA (Teprotumumab by Horizon Biologics), a fully human monoclonal antibody for the treatment of Thyroid Eye Disease (TED).
Dr. Perman will discuss whether this new treatment modality is appropriate for your condition, and if so, will facilitate your treatment protocol.